Maysiglu

Sitagliptin, the active ingredient in Maysiglu, is a dipeptidyl peptidase-4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycemic control when combined with diet and exercise.

GNH USA supplies Maysiglu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through regulated distribution channels, and offers reliable quality assurance for each batch.

Sitagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): lowers fasting plasma glucose and reduces HbA1c levels. - Type 2 diabetes mellitus (combined with metformin): enhances overall glycemic control. - Type 2 diabetes mellitus (as add‑on therapy): improves post‑prandial glucose regulation.

Sitagliptin may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea - Headache - Upper respiratory tract infection - Nasopharyngitis

Serious or Rare Side Effects: - Acute pancreatitis - Severe hypersensitivity reactions (including anaphylaxis) - Bullous pemphigoid - Marked hypoglycemia, especially when combined with insulin or sulfonylureas

When prescribing sitagliptin, clinicians should consider several safety measures.

- Renal function: assess baseline renal function and adjust use in severe impairment. - Pancreatitis: discontinue if signs of acute pancreatitis develop. - Hypersensitivity: monitor for rash, angioedema, or anaphylactic reactions. - Concomitant hypoglycemics: use caution with insulin or sulfonylureas to avoid severe hypoglycemia. - Hepatic impairment: evaluate liver function; use with caution in moderate hepatic disease. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Sitagliptin can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin: concurrent use may cause severe hypoglycemia. - Sulfonylureas: combined therapy can increase risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Rifampin: strong enzyme inducer that may reduce sitagliptin plasma concentrations. - Digoxin: sitagliptin may increase digoxin serum levels; monitor therapeutic range. - Diuretics (e.g., thiazides): may affect renal clearance of sitagliptin; monitor renal function.